Jonathan Zalevsky, an insider at Nektar Therapeutics (NASDAQ:NKTR), sold 180 shares of the company’s stock on February 18, 2024. The shares were sold at an average...
Gossamer Bio is set to report the results of its Phase 3 clinical trial focused on pulmonary arterial hypertension (PAH), a progressive lung disease, by the...
